New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 4, 2012
06:46 EDTSRPT, PPHMStocks with implied volatility below IV index mean; PPHM SRPT
Stocks with implied volatility below IV index mean; Peregrine Pharmaceuticals (PPHM), Sarepta (SRPT) according to iVolatility.
News For SRPT;PPHM From The Last 14 Days
Check below for free stories on SRPT;PPHM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2013
07:34 EDTSRPTUBS to host a conference
Subscribe for More Information
May 20, 2013
08:50 EDTPPHMPeregrine reaches agreement with FDA on Phase 3 trial design for Bavituximab
Peregrine Pharmaceuticals announced that it has reached agreement with the FDA on a Phase III registration trial design of the company's lead clinical immunotherapeutic candidate bavituximab in second-line non-small cell lung cancer. The trial design was supported by promising data from a Phase IIb trial in patients treated with bavituximab plus docetaxel. The Phase III clinical trial will be a randomized, double-blind, placebo-controlled trial evaluating bavituximab plus docetaxel versus docetaxel alone enrolling approximately 600 patients at sites worldwide. The trial will enroll Stage IIIB/IV non-squamous, NSCLC patients who have progressed after standard front-line treatment. The primary endpoint of the trial will be overall survival.
08:40 EDTPPHMPeregrine trading halted, pending news
Subscribe for More Information
May 16, 2013
07:29 EDTSRPTLeerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17.
May 9, 2013
12:21 EDTSRPTSarepta climbs after saying documents to be submitted this month
Subscribe for More Information
07:29 EDTSRPTSarepta reports Q1 EPS (41c), consensus (62c)
Reports Q1 revenue $4.5M, consensus $5.85M.
May 7, 2013
13:15 EDTSRPTOptions with increasing implied volatility: CVRR SRPT PGH TWO GDI HNZ
Subscribe for More Information
08:59 EDTSRPTSarepta initiates dosing in Phase I study of Marburg virus treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.